Market Research Logo

Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)

Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Fatty Liver Disease Market on the basis of Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor), By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer), By Region (North America, Europe, Asia Pacific and ROW) and By Country (U.S., Canada , U.K., France, Germany, China, Japan, India, Brazil, South Africa and Saudi Arabia).

Over the recent years, the global fatty liver disease incidence has been growing rapidly with increase in prevalence of obesity, type II diabetes along with rising consumption of alcohol. Globally, the growth in the fatty liver disease market is driven by rising awareness among people by government organizations and private companies, heavy investments by pharmaceutical companies for the development of drugs along with launch of drugs for NASH in the forecasted period.

According to Azoth Analytics research report, the report “Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)” analyses the Global Fatty Liver Disease Market, Analysis By Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis or ASH), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) and By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer). The global market is projected to display a robust growth represented by a CAGR of 22.67% during 2017 – 2022, chiefly driven by rising prevalence of obesity, diabetes and hypertension, rising clinical trials in Asian countries, heavy investments by government of different countries in their health care sector, rising research in developing the different health care machines and methodology for the detection of alcohol and non-alcohol steatosis at its early stage.

The report titled, “Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)” has covered and analysed the potential of Global Fatty Liver Disease Market, NASH and NAFLD markets and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global fatty liver disease market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

  • Fatty Liver Disease market
  • Breakdown –By NAFLD Stages (2012-2022): (Steatosis , NASH)
  • Breakdown –By ALD Stages (2012-2022): (Steatosis, Alcohol Hepatitis)
  • Breakdown by ALD Drugs (2012-2022): (Opioid Antagonist ,Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor)
  • Breakdown By NAFLD Drug (2012-2022): (Antioxidants Thiazolidinedione, Biguanides, Hypolipidemic Agents, FXR receptor agonist, Elafibranoer)
Regional Markets – North America, Europe, APAC, ROW (Actual Period: 2012-2016 Forecast Period: 2017-2022)
  • Fatty Liver Disease market
  • Fatty Liver Disease market By Type (ALD, NAFLD)
  • Breakdown by ALD Drugs (2012-2022)
  • Breakdown By NAFLD Drug (2012-2022)
Country Analysis - UK, Germany, France, India, China, Japan, Brazil, Saudi Arabia, South Africa, U.S. and Canada – (Actual Period: 2012-2016, Forecast Period: 2017-2022)
  • Fatty Liver Disease market
  • Fatty Liver Disease market By Type (ALD, NAFLD)
Other Report Highlights
  • Market Dynamics – Trends, Drivers, Challenges
  • Policy and Regulation
  • Company Analysis – Pfizer, Gilead Sciences ,Astra Zenca, Immuron, Novartis,Takeda, Allergan , Intercept Pharmaceuticals, Conatus
Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.


1. Research Methodology
2. Executive Summary
3. Strategic Recommendation
3.1. Focus on Asia Region
3.2. Focus on drug development for NASH and Alcohol Hepatitis
3.3. Focus on early Stage detection of Alcohol and Non Alcoholic Steatosis
4. Fatty Liver Market Outlook
Table 1: History of Fatty Liver Disease
Table 2: Therapeutic Algorithm for Management of Alcoholic Hepatitis
Table A: Causes of NAFLD Infection
Table 3: Treatment Algorithm of NAFLD
5. Global Fatty Liver Disease Market: Growth and Forecast
5.1. By Value (2012-2016)
Table 4: Global Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Million)
5.2. By Value (2017-2022)
Table 5: Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million)
6. Global Fatty Liver Disease – Analysis By Type
6.1. Global Fatty Liver Disease Market -By Type (Alcoholic Fatty Liver Disease (ALD), Non Alcoholic Fatty Liver Disease (NAFLD)): Breakdown (%)
6.1.1. Global Fatty Liver Disease Market-By Type, 2016 (%)
Table 6: Global Fatty Liver Disease Market Size, By Type, 2016 (%)
6.1.2. Global Fatty Liver Disease Market-By Type, 2022 (%)
Table 7: Global Fatty Liver Disease Market Size, By Type, 2022F (%)
6.2. Global Fatty Liver Disease–By Type, By Value
6.2.1. Global Alcoholic Fatty Liver Disease Market
6.2.1.1. By Value (2012-2022)
Table 8: Global Alcoholic Fatty liver Market Service Market, By Value, 2012-2016 (USD Billion)
Table 9: Global Alcoholic Fatty liver Market Service Market, By Value, Forecast, 2017E-2022F (USD Billion)
Table 10: Beer Consumption, Billion Liters, 2014
6.2.2. Global Non Alcoholic Fatty Liver Disease Market
6.2.2.1. By Value (2012-2022)
Table 11: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, 2012-2016 (USD Billion)
Table 12: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion)
Table 13: Global Diabetic Population, By Region, 2015 (Million)
7. Global Alcoholic Fatty Liver Disease Market – Analysis By Stages
7.1. Global Alcoholic Fatty Liver Disease Market -By Stages (Alcoholic Steatosis and Alcoholic Steatohepatitis): Breakdown (%)
7.1.1. Global Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%)
Table 14: Global Alcoholic Liver Disease Market Size, By Stage, 2016 (%)
7.1.2. Global Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%)
Table 15: Global Alcoholic liver Disease Market Size, By Type, 2022F (%)
7.2. Global Alcoholic Fatty Liver Disease Market -By Stages, By Value
7.2.1. Global Alcoholic Steatosis Market
7.2.1.1. By Value (2012-2022)
Table 16: Global Alcoholic Steatosis Treatment, By Value, 2012-2016 (USD Billion)
Table 17: Global Alcoholic Steatosis Treatment, By Value, Forecast, 2017E-2022F (USD Billion)
Table 18: World Alcohol Consumption, Liters per Capita, 2014-2016
Table B: Quantity of Alcohol in Standard Drink
7.2.2. Global Alcoholic Steatohepatitis Market
7.2.2.1. By Value (2012-2022)
Table 19: Global Alcoholic Staetohepatitis Market, By Value, 2012-2016 (USD Billion)
Table 20: Global Alcoholic Staetohepatitis Market, By Value, Forecast, 2017E-2022F (USD Billion)
8. Global Non Alcoholic Fatty Liver Disease Market–Analysis By Stages
8.1. Global Non Alcoholic Fatty Liver Disease Market -By Stages (Non Alcoholic Steatosis and Non Alcoholic Steatohepatitis) : Breakdown(%)
8.1.1. Global Non Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%)
Table 21: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%)
8.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%)
Table 22: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2022F (%)
8.2. Global Non Alcoholic Fatty Liver Disease Market -By Stages , By Value
8.2.1. Global Non Alcoholic Steatosis Market
8.2.1.1. By Value (2012-2022)
Table 23: Global Non Alcoholic Steatosis Treatment Market, By Value, 2012-2016 (USD Billion)
Table 24: Global Non Alcoholic Steatosis Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion)
8.2.2. Global Non Alcoholic Steatohepatitis Market
8.2.2.1. By Value (2012-2022)
Table 25: Global NASH Market, By Value, 2012-2016 (USD Billion)
Table 26: Global NASH Market, By Value, Forecast, 2017E-2022F (USD Billion)
9. Global Alcoholic Fatty Liver Disease Market –By Drugs
9.1. Global Alcoholic Fatty Liver Disease Market -By Drugs (Opoid Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor): Breakdown (%)
9.1.1. Global Alcoholic Fatty Liver Disease Market -By Drugs, 2016 (%)
Table 27: Global Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)
9.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2022 (%)
Table 28: Global In-flight Catering Service Market Size, By Airline Type, 2022F (%)
9.2. Global Alcoholic Fatty Liver Disease Market -By Drugs, By Value
9.2.1. Global Opioid Antagonist Drug Market
9.2.1.1. By Value (2012-2022)
Table 29: Global Opioid Antagonist Drug Market, By Value, 2012-2016 (USD Billion)
Table 30: Global Opioid Antagonist Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
9.2.2. Global Pentoxifylline Drug Market
9.2.2.1. By Value (2012-2022)
Table 31: Global Pentoxifylline Drug Market, By Value, 2012-2016 (USD Billion)
Table 32: Global Pentoxifylline Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
9.2.3. Global Glucocorticoid Drug Market
9.2.3.1. By Value (2012-2022)
Table 33: Global Glucocoticoid Drug Market, By Value, 2012-2016 (USD Billion)
Table 34: Global Glucocorticoid Drug Market, By Value Forecast, 2017E-2022F (USD Billion)
9.2.4. Global Antioxidants Drug market
9.2.4.1. By Value (2012-2022)
Table 35: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)
Table 36: Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
9.2.5. Global Granulocyte colony stimulating factor Drug Market
9.2.5.1.By Value (2012-2022)
Table 37: Global Granulocyte Colony Stimulating Factor Drug Market, By Value, 2012-2016 (USD Billion)
Table 38: Global Granulocyte Colony Stimulating Factor Drug Market , By Value, Forecast, 2017E-2022F(USD Billion)
10. Global Non Alcoholic Fatty Liver Disease Market –By Drugs
10.1. Global Non Alcoholic Fatty Live Disease Market -By Drugs (Antioxidants, Thiazolidinedione, Biguanides, Lipid Lowering Agents, FXR Receptor Agonist, Elafibranor): Breakdown (%)
10.1.1. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2016 (%)
Table 39: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)
10.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2022 (%)
Table 40: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2022F (%)
10.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs , By Value
10.2.1. Global Antioxidants Drug Market
10.2.1.1. By Value (2012-2022)
Table 41: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)
Table 42: Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022 (USD Billion)
10.2.2. Global Thiazolidinedione Drug Market
10.2.2.1. By Value (2012-2022)
Table 43: Global Thiazolidinedione Drug Market, By Value, 2012-2016 (USD Billion)
Table 44: Global Thiazolidinedione Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
10.2.3. Global Biguanides Drug Market
10.2.3.1. By Value (2012-2022)
Table 45: Global Biguandies Drug Market, By Value, 2012-2016 (USD Billion)
Table 46: Global Biguandies Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
10.2.4. Global Hypolipidemic Agents Drug market
10.2.4.1. By Value (2012-2022)
Table 47: Global Hypolipidemic Drug Market, By Value, 2012-2016 (USD Billion)
Table 48: Global Hypolipidemic Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
10.2.5. Global FXR Receptor Agonist Drug Market
10.2.5.1. By Value (2012-2022)
Table 49: Global FXR Receptor Agonist Drug Market, By Value, 2012-2016 (USD Billion)
Table 50: Global FXR Receptor Agonist Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
10.2.6. Global Elafibranor Drug Market
10.2.6.1. By Value (2012-2022)
Table 51: Global Elafibranor Drug Market, By Value, 2012-2016 (USD Billion)
Table 52: Global Elafibranor Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
11. Global Fatty Liver Disease Market – Pipeline Analysis (By developer, Phase and indication)
Table C: Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table D: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table E: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table F: NASH Multi Therapy Treatment Market Analysis, By Drug, Developer, Phase, Indication, Status
12. Global Fatty Liver Disease Market – Regional Analysis
12.1. Global Fatty Liver Disease Market -By Regional: Breakdown (%)
12.1.1. Global Fatty Liver Disease Market -By Region, 2016(%)
Table 53: Global Fatty Liver Disease Market Size and Share, By Region, 2016
12.1.2. Global Fatty Liver Disease Market -By Region, 2022 (%)
Table 54: Global Fatty Liver Disease Market Size and Share, By Segments, 2022F
13. North America Fatty liver Disease Market - An Analysis
13.1. By Value (2012-2022)
Table 55: North America Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 56: North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Table 57: North America Healthcare Expenditure, 2011-2014 (% of GDP)
Table 58: North America Population Age 15-64 2015 (% of Total)
13.2. North America Fatty liver Disease Market – By Type, By Value
Table 59: North America Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
13.3. North America Fatty liver Disease Market – By ALD Drug, By Value
Table 60: North America Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
13.4. North America Fatty liver Disease Market – By NAFLD Drug, By Value
Table 61: North America Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
14. North America Fatty Liver Disease Market –By Country Analysis
14.1. North America Fatty Liver Disease Market –By Country, 2012-2016 (%)
Table 62: North America Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
14.2. North America Fatty Liver Disease Market –By Country, 2017E-2022F (%)
Table 63: North America Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
14.3. United States Fatty Liver Disease Market – By Value(2012-2022)
Table 64: United States Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 65: United States Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Table 66: Percentage of United states adults who had at least one heavy drinking day, 2011-2015
Table 67: United States Alcohol Liters Per Capita Consumption, 2011-2015
14.3.1. United States Fatty Liver Disease Market By Type, By Value
Table 68: United States Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
14.4. Canada Fatty Liver Disease Market – By Value(2012-2022)
Table 69: CanadaFatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 70: Canada Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
14.4.1. Canada Fatty Liver Disease Market By Type, By Value
Table 71: Canada Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Table 72: Canada Alcohol Liters Per Capita Consumption, 2011-2015
Table 73: Prevalence of Obese and overweight Population, By Age, 2014 (%)
15. Asia Pacific Fatty liver Disease Market- An Analysis
15.1. By Value (2012-2022)
Table 74: Asia Pacific Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 75: Asia PacificFatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Table 76: Obesity Prevalence in Asian Countries, 2014 (%)
15.2. Asia Pacific Fatty liver Disease Market – By Type, By Value
Table 77: Asia Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
15.3. Asia Pacific Fatty liver Disease Market – By ALD Drug, By Value
Table 78: Asia Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
15.4. Asia Pacific Fatty liver Disease Market – By NAFLD Drug, By Value
Table 79: Asia Pacific Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
16. Asia Pacific Fatty Liver Disease Market –By Country Analysis
16.1. Asia Pacific Fatty Liver Disease Market –By Country, 2012-2016 (%)
Table 80: Asia Pacific Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
16.2. Asia Pacific Fatty Liver Disease Market –By Country, 2017E-2022F (%)
Table 81: Asia Pacific Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
16.3. India Fatty Liver Disease Market – By Value(2012-2022)
Table 82: India Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 83: India Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Table 84: Percentage of United States adults who had at least one heavy drinking day, 2011-2015
Table 85: India Alcohol Liter per capita Consumptions, 2015-2016
16.3.1. India Fatty Liver Disease Market By Type, By Value
Table 86: India Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
16.4. China Fatty Liver Disease Market – By Value(2012-2022)
Table 87: China Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 88: China Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Table 89: Health expenditure in China, 2011-2015 (USD Billion)
Table 90: China Alcohol Liter per capita Consumptions, 2015-2016
16.5. Japan Fatty Liver Disease Market – By Value (2012-2022)
Table 91: Japan Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 92: Japan Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
16.5.1. Japan Fatty Liver Disease Market By Type, By Value
Table 93: Japan Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
16.6. Rest of Asia Fatty Liver Disease Market-By Value (2012-2022)
Table 94: Rest of Asia Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 95: Rest of Asia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
17. Europe Pacific Fatty liver Disease Market
17.1. By Value (2012-2022)
Table 96: Europe Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 97: Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Table 98: Europe Diabetes Prevalence, By Country, 2015 (% of Population Aged 20 to 79)
Table 99: EU Health Expenditure Per Capita, 2011-2014 (USD)
Table 100: Breakdown of Total Health Expenditure in Europe (%)
17.2. Europe Fatty liver Disease Market – By Type, By Value
Table 101: Europe Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
17.3. Europe Fatty liver Disease Market – By ALD Drug, By Value
Table 102: Europe Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
17.4. Europe Fatty liver Disease Market – By NAFLD Drug, By Value
Table 103: Europe Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
18. Europe Fatty Liver Disease Market –By Country Analysis
18.1. Europe Fatty Liver Disease Market –By Country, 2012-2016 (%)
Table 104: Europe Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
18.2. Europe Fatty Liver Disease Market –By Country, 2017E-2022F (%)
Table 105: Europe Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
18.3. United Kingdom Fatty Liver Disease Market – By Value (2012-2022)
Table 106: United Kingdom Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 107: United Kingdom Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
18.3.1. United Kingdom Fatty Liver Disease Market By Type, By Value
Table 108: United Kingdom Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Table 109: Alcohol Related Disease Death, 2015
Table 110: Diabetes Prevalence in U.K. 2015
Table 111: Five Day Drinking Prevalence By Age, (%), 2014-2015
18.4. Germany Fatty Liver Disease Market – By Value (2012-2022)
Table 112: Germany Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 113: Germany Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Table 114: Private Healthcare Spending in Germany, US Dollar/capita 2011 to 2015
Table 115: Diabetes Prevalence in 55-74 age people in Germany, Forecast 2030F
Table 116: Alcohol Consumption per capita, 2012-2016 (liter) in Germany
18.4.1. Germany Fatty Liver Disease Market By Type, By Value
Table 117: Germany Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Million)
18.5. France Fatty Liver Disease Market – By Value (2012-2022)
Table 118: France Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 119: France Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
18.5.1. France Fatty Liver Disease Market By Type, By Value
Table 120: France Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Million)
18.6. Rest of Europe Fatty Liver Disease Market-By Value (2012-2022)
Table 121: Rest Of Europe Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 122: Rest of Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
19. Rest of World Fatty liver Disease Market
19.1. By Value (2012-2022)
Table 123: Rest of World Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 124: Rest of World Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
19.2. Rest of World Fatty liver Disease Market – By Type, By Value
Table 125: Rest of World Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
19.3. Rest of World Fatty liver Disease Market – By ALD Drug, By Value
Table 126: Rest of World Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
19.4. Rest of World Fatty liver Disease Market – By NAFLD Drug, By Value
Table 127: Rest of world Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
20. Rest of World Fatty Liver Disease Market –By Country Analysis
20.1. Rest of World Fatty Liver Disease Market –By Country, 2012-2016 (%)
Table 128: Rest of World Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
20.2. Rest of World Fatty Liver Disease Market –By Country, 2017E-2022F (%)
Table 129: Rest of World Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
20.3. Saudi Arabia Fatty Liver Disease Market – By Value (2012-2022)
Table 130: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 131: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
20.3.1. Saudi Arabia Fatty Liver Disease Market By Type, By Value
Table 132: Saudi Arabia Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Table 133: Saudi Arabia Prevalence of Obesity Forecast 2022 (%)
20.4. South Africa Fatty Liver Disease Market – By Value (2012-2022)
Table 134: South Africa Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 135: South Africa Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
20.4.1. South Africa Fatty Liver Disease Market By Type, By Value
Table 136: South Africa Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
20.5.Brazil Fatty Liver Disease Market – By Value (2012-2022)
Table 137: Brazil Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 138: Brazil Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
20.5.1. Brazil Fatty Liver Disease Market By Type, By Value
Table 139: Brazil Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
20.6. Others Fatty Liver Disease Market-By Value (2012-2022)
Table 140: Others Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Table 141: Others Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
21. Market Dynamics
21.1. Drivers
21.2. Challenges
22. Market Trends
23. Policy and Regulations
24. Porter Five Force
25. SWOT Analysis
26. Company Profiling
26.1. Pfizer
Table 142: Pfizer Segmental Breakup, 2016 (%)
Table 143: Pfizer Sales, By Region, 2016 (%)
26.2. Conatus Pharmaceuticals
26.3. Novartis
Table 144: Novartis Sales, By Segment 2015 (%)
Table 145: Novartis Sales, By Region, 2015 (%)
Table 146: Novartis Pharmaceuticals Sales, By Franchise, 2015 (%)
26.4. Intercept Pharmaceuticals
26.5. Allergan
26.6. Immuron
26.7. Takeda
Table 147: Takeda Segmental Breakup
Table 148: Takeda Revenue, 2013-2016 (USD Million)
26.8. Gilead Sciences
Table 149: Gilead Sciences Product Sales, 2016 (%)
Table 150: Gilead Sciences HCV Product Sales, 2014-2016 (USD Billion)
26.9. Genfit

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report